Opisthotonos following propofol: a nonepileptic perspective and treatment strategy.
In this report of opisthotonos during recovery from propofol anaesthesia, we relate clinical observations with scientific considerations, and propose a strategy for treatment of this rare side effect. Following a brief operative procedure, a healthy 29-yr-old woman developed recurrent opisthotonos while recovering from anaesthesia with alfentanil, propofol, and nitrous oxide. In contrast to accumulating reports, the patient remained conscious during each episode of back extension and retrocollis. The preservation of consciousness and similarities to strychnine-induced opisthotonos suggest to us that the mechanism may have a brainstem and spinal origin. Recent investigations show that propofol potentiates the inhibitory transmitters glycine and gamma-aminobutyric acid (GABA) which would enhance spinal inhibition during anaesthesia. Postanaesthetic opisthotonos, however, may be due to a propofol-induced tolerance to inhibitory transmitters. This rebound phenomenon would lead to an acute, enduring refractoriness in inhibitory pathways of the brainstem and spinal cord, resulting in increased activity of extensor motoneurons. We recommend a therapeutic strategy that restores inhibition by glycine and GABA at multiple sites; the preferred therapeutic agents would be diazepam and physostigmine. The episodes are usually short-lived, but two of the reviewed 17 patients developed recurrent retrocollis for four and 23 days following antiepileptic drug therapy. Since high doses of phenytoin and carbamazepine can result in opisthotonos, we recommend that anticonvulsants be reserved for postanaesthetic patients with electroencephalographic evidence of seizure activity.
Ries
C R
CR
Department of Anaesthesia, University of British Columbia, Vancouver.
Scoates
P J
PJ
Puil
E
E
D000328:Adult; D000762:Anesthesia Recovery Period; D000771:Anesthesia, Intravenous / Q000009:adverse effects*; D002985:Clinical Protocols; D003243:Consciousness; D005260:Female; D006801:Humans; D009127:Muscle Rigidity / Q000139:chemically induced; D015742:Propofol / Q000009:adverse effects*; D018079:Receptors, GABA / Q000187:drug effects; D018009:Receptors, Glycine / Q000187:drug effects; D013035:Spasm / Q000139:chemically induced* / Q000188:drug therapy
D018079:Receptors, GABA; D018009:Receptors, Glycine; D015742:Propofol